The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to $1.2 billion by 2030, with a CAGR of 25.6%. This market is driven by a growing understanding of microbiome-disease correlations and increasing demand for microbiome-targeted therapies and diagnostics.
The report analyzes the market for human microbiome-based drugs and diagnostics, focusing on trends, segmentation, and applications. It covers drug delivery methods, diagnostic tools, and applications in areas like infectious diseases, cancer, and metabolic disorders. The market is expanding due to the rising awareness of the microbiome’s impact on health.
Factors driving market growth include evidence of microbiome-disease correlations, the use of microbiome diagnostics for disease prevention, and the development of drugs and diagnostics for skin and lung microbiomes. There is also a growing interest in direct-to-consumer microbiome testing, promoting personalized wellness solutions.
Key players in the market include companies like BIOMEBANK, ENTEROME, ILLUMINA INC., and THERMO FISHER SCIENTIFIC INC. These companies are leading efforts to develop microbiome-based drugs and diagnostics for various health conditions. The report also highlights emerging startups in this industry.
The market for human microbiome-based drugs and diagnostics is projected to reach $1.2 billion by 2030, with a CAGR of 25.6%. This growth is fueled by increasing clinical evidence of microbiome impacts on health and the use of microbiome diagnostics for disease prevention. North America currently holds the largest market share.
For more information on the global market for human microbiome-based drugs and diagnostics, and related reports on microbiome sequencing and DNA sequencing, contact BCC Research at [email protected]. BCC Research provides objective market research to help businesses make informed decisions in the healthcare industry.
Read more at GlobeNewswire: Human Microbiome Market to Grow at 25.6% CAGR Through 2030